Phase 2 proof-of-concept study RTB101 in an aging-related disease.
Phase of Trial: Phase II
Latest Information Update: 05 Apr 2018
At a glance
- Drugs Dactolisib (Primary)
- Indications Immunodeficiency disorders; Respiratory tract infections
- Focus Therapeutic Use
- 05 Apr 2018 Patient gender and indication are assumed.
- 05 Apr 2018 New trial record
- 29 Mar 2018 According to a resTORbio media release, this trial is anticipated to start in 2018.